RedHill Announces New Opaganib Chinese Patent Against Ebola Virus Valid Through 2035
The new Chinese patent for opaganib as a therapy for inhibition of single-stranded RNA virus replication (notably Ebola Disease Virus) is valid through 2035 and adds to opaganib's strong global intellectual property portfolio across multiple …